[Transcatheter closure of atrial septal defects in 40 pediatric patients]
Dong-an Deng1, Xian-yang Zhu, Chuan-ju Hou
1Department of Internal Medicine For Congenital Heart Diseases, Shenyan Military General Hospital, Shenyang 110016, China.
Insights
Transcatheter closure of atrial septal defect (ASD) using the Amplatzer device is a safe and effective treatment for pediatric patients. This minimally invasive procedure showed a 100% success rate with significant symptom improvement.
Area of Science:
- Cardiology
- Pediatric Cardiology
- Interventional Cardiology
Background:
- Atrial septal defect (ASD) is a common congenital heart defect.
- Transcatheter closure offers a minimally invasive alternative to surgical repair.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of the AGA-Amplatzer occlusion device for transcatheter closure of ASD in pediatric patients.
Main Methods:
- Forty pediatric patients with ASD underwent transcatheter closure using the AGA-Amplatzer device.
- Device sizing was based on balloon-stretched ASD diameter measurements obtained via echocardiography (TTE/TEE) and right heart catheterization.
Main Results:
- A 100% procedural success rate was achieved with successful implantation in all 40 patients.
- No complications or residual shunts were observed post-procedure.
- Patients demonstrated marked improvement in clinical symptoms, cardiac murmurs, and diagnostic findings (ECG, echocardiography, X-ray) after a short follow-up period.
Conclusions:
- The AGA-Amplatzer occlusion device is a safe and highly efficient option for transcatheter closure of ASD in the pediatric population.
- This technique provides excellent clinical outcomes and is well-tolerated by young patients.
Objective:
To evaluate the clinical efficiency of transcatheter closure of atrial septal defect (ASD) with AGA-Amplatzer occlusion device in pediatric patients.
Methods:
Forty patients with ASD, 16 males, 24 females, at a mean age of 10.2 years (ranged from 3 to 15 years of age) and with a mean weight of 35.8 kg (ranged from 11 to 87 kg) were studied. Six cases were complicated with pulmonary stenosis (PS), 1 was complicated with ventricular tachycardia (VT). Right heart catheterizations were done in 40 patients for measuring the pressures of right ventricle and pulmonary artery. The balloon diameter of ASD was measured using balloon catheter with guiding wire. The diameter of ASD was measured by TTE and/or TEE, ascertaining the location and size of ASD. Amplatzer occlusion device was sized to be equal to or 1 - 2 mm more than the diameter of balloon stretched.
Results:
All patients had successful implantation of the Amplatzer device. The success rate was 100%. The diameter measured by TTE was 7 - 30 mm (mean 17.12 mm). The diameter measured by TEE was 7 - 32 mm (mean 18.44 mm). The diameter of balloon stretched of ASD was 8 - 34 mm. Of the 40 cases, 6 were complicated with PS and accepted percutaneous balloon valvuloplasty (PBPV). One case was complicated with VT and accepted radiofrequency catheter ablation (RFCA). Neither complication nor residual shunt was found in any of the patients. The patients were recovered and followed up for 3 or 4 days after deployment of the Amplatzer device. Clinical symptom, cardiac murmur, and findings in ECG, echocardiography and X-ray were improved markedly.
Conclusion:
AGA-Amplatzer occlusion device is safe and efficient in pediatric patients with ASD.
